144 related articles for article (PubMed ID: 37022561)
1. L-asparaginase as an efficient salvage therapy for refractory acute myeloid leukemia with chromosome 7 abnormalities: a case series.
Noguchi K; Ikawa Y; Takenaka M; Sakai Y; Fujiki T; Kuroda R; Maeba H; Goto H; Kitoh T; Wada T
Int J Hematol; 2023 Sep; 118(3):406-410. PubMed ID: 37022561
[TBL] [Abstract][Full Text] [Related]
2. Identification of a cytogenetic and molecular subgroup of acute myeloid leukemias showing sensitivity to L-Asparaginase.
Bertuccio SN; Serravalle S; Astolfi A; Lonetti A; Indio V; Leszl A; Pession A; Melchionda F
Oncotarget; 2017 Dec; 8(66):109915-109923. PubMed ID: 29299118
[TBL] [Abstract][Full Text] [Related]
3. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
Ahmed T; Holwerda S; Klepin HD; Isom S; Ellis LR; Lyerly S; Manuel M; Dralle S; Berenzon D; Powell BL; Pardee TS
Leuk Res; 2015 Sep; 39(9):945-9. PubMed ID: 26154683
[TBL] [Abstract][Full Text] [Related]
4. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
Kantarjian HM; DiNardo CD; Nogueras-Gonzalez GM; Kadia TM; Jabbour E; Bueso-Ramos CE; O'Brien SM; Konopleva M; Jain NB; Daver NG; Shpall EJ; Champlin RE; Simkins A; Garcia-Manero G; Keating MJ; Huang X; Cortes JE; Pierce SA; Ravandi F; Freireich EJ
Cancer; 2018 Jun; 124(12):2534-2540. PubMed ID: 29645075
[TBL] [Abstract][Full Text] [Related]
5. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
6. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study.
Hasle H; Alonzo TA; Auvrignon A; Behar C; Chang M; Creutzig U; Fischer A; Forestier E; Fynn A; Haas OA; Harbott J; Harrison CJ; Heerema NA; van den Heuvel-Eibrink MM; Kaspers GJ; Locatelli F; Noellke P; Polychronopoulou S; Ravindranath Y; Razzouk B; Reinhardt D; Savva NN; Stark B; Suciu S; Tsukimoto I; Webb DK; Wojcik D; Woods WG; Zimmermann M; Niemeyer CM; Raimondi SC
Blood; 2007 Jun; 109(11):4641-7. PubMed ID: 17299091
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols.
Sitges M; Boluda B; Garrido A; Morgades M; Granada I; Barragan E; Arnan M; Serrano J; Tormo M; Miguel Bergua J; Colorado M; Salamero O; Esteve J; Benavente C; Pérez-Encinas M; Coll R; Martí-Tutusaus JM; Brunet S; Sierra J; Ángel Sanz M; Montesinos P; Ribera JM; Vives S;
Eur J Haematol; 2020 Aug; 105(2):138-147. PubMed ID: 32243655
[TBL] [Abstract][Full Text] [Related]
8. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of Factors Influencing Prognosis of 87 Adults with Ph Chromosome Negative ALL].
Li J; Zhang ZB; Liu ZR; Yang M; Nie YX; Wu MM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1011-1015. PubMed ID: 30111399
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis.
Wang ZY; Gao WH; Zhao HJ; Yin CR; Wang ZW; Tian L; Wang L; Wang LN; Jiang JL; Devillier R; Wan M; Wang JM; Huang PP; Blaise D; Hu J
Acta Haematol; 2022; 145(4):419-429. PubMed ID: 35231903
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22).
Lai YY; Qiu JY; Jiang B; Lu XJ; Huang XJ; Zhang Y; Liu YR; Shi HL; Lu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):733-40. PubMed ID: 16277833
[TBL] [Abstract][Full Text] [Related]
12. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
14. Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults.
Min GJ; Kim HJ; Yoon JH; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1621-1628. PubMed ID: 29698793
[TBL] [Abstract][Full Text] [Related]
15. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
[TBL] [Abstract][Full Text] [Related]
16. Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.
Armistead PM; de Lima M; Pierce S; Qiao W; Wang X; Thall PF; Giralt S; Ravandi F; Kantarjian H; Champlin R; Estey E
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1431-8. PubMed ID: 19822303
[TBL] [Abstract][Full Text] [Related]
17. Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia.
Buaboonnam J; Cao X; Pauley JL; Pui CH; Ribeiro RC; Rubnitz JE; Inaba H
Pediatr Blood Cancer; 2013 Jul; 60(7):1161-4. PubMed ID: 23335430
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).
Schnetzke U; Fix P; Spies-Weisshart B; Schrenk K; Glaser A; Fricke HJ; La Rosée P; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1391-7. PubMed ID: 24728467
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of Venetoclax in the treatment of 25 patients with recurrent hematologic malignancies after an allogeneic hematopoietic stem cell transplantation].
Chen X; Liu ZY; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; He Y; Wei JL; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):542-549. PubMed ID: 36709130
[No Abstract] [Full Text] [Related]
20. Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
Ye P; Pei R; Jin J; Sun J; Li K; Cao J; Zhou D; Lu Y
Ann Hematol; 2019 Sep; 98(9):2073-2080. PubMed ID: 31201514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
